IMPORTANCE Dexmedetomidine provides sedation for patients undergoing ventilation; however, its effects on mortality and ventilator-free days have not been well studied among patients with sepsis.
D exmedetomidine, a highly selective α 2 -adrenergic agonist, is a unique sedative agent compared with γ-aminobutyric acid receptor agonists. Dexmedetomidine can improve patients' ability to communicate pain compared with midazolam and propofol. Therefore, dexmedetomidine is likely to be useful for light sedation. 1 The analgesic effects of dexmedetomidine or the reduction of other deliriogenic sedatives may lessen both agitation and delirium.
2 Furthermore, several studies have shown that dexmedetomidine can suppress inflammatory reactions and protect organs in both animals and humans. [3] [4] [5] [6] [7] Particularly, the Maximizing Efficacy of Targeted Sedation and Reducing Neurological Dysfunction (MENDS) randomized clinical trial showed in a subgroup analysis that patients with sepsis treated with dexmedetomidine had an improved 28-day mortality rate compared with those receiving lorazepam. 8 Therefore, it was hypothesized that dexmedetomidine would improve patient-oriented outcomes among patients with sepsis. The Dexmedetomidine for Sepsis in Intensive Care Unit (ICU) Randomized Evaluation (DESIRE) trial was conducted to evaluate whether a sedation strategy with dexmedetomidine would improve mortality and ventilator-free days during the 28 days after the initiation of ventilation among ICU patients with sepsis.
Methods

Study Design
The DESIRE trial was an investigator-initiated, multicenter, open-label randomized clinical trial conducted among patients who had sepsis requiring mechanical ventilation for more than 24 hours. The trial was designed to assess the effects of a sedation strategy with dexmedetomidine on mortality and ventilator-free days during the 28-day period after initiation of ventilation. The trial was conducted in 8 ICUs in Japan. The first patient was enrolled in February 2013 and the trial was completed in January 2016. This study was approved by the institutional review boards of Wakayama Medical University and each participating institution. Written informed consent was obtained from patients or patients' families before randomization. Patients did not receive a stipend for participation in this trial. The study protocol is available in Supplement 1.
Patients
Patients who were aged 20 years or older, had sepsis, and needed mechanical ventilation for at least 24 hours (at the discretion of ICU physicians) were eligible for the study. Mechanical ventilation included both invasive and noninvasive ventilation (ie, ventilation with a nasal mask, face mask, head mask, or cuirass). Sepsis was defined as systemic inflammatory response syndrome due to infection. 9 Because fluid resuscitation and antisepsis treatments are necessary for acute pancreatitis (similar to an infection), cases of acute pancreatitis were included as an infection whereas cases of burns or heatstroke were not. Soft tissue infection including necrotizing fasciitis and Fournier gangrene were considered to take unusually longer treatment for debridement in the ICU. Patients were excluded if they (1) had severe chronic liver disease (Child-Pugh grade B or C); (2) had acute myocardial infarction or severe heart failure (New York Heart Association functional class 4); (3) had drug dependence or alcoholism or a psychological illness or severe cognitive dysfunction; or (4) were pregnant or lactating or were allergic to dexmedetomidine. Detailed inclusion and exclusion criteria are provided in the trial protocol (Supplement 1).
Randomization and Intervention
Eligible patients were randomly assigned to receive either the sedation strategy with dexmedetomidine or the sedation strategy without dexmedetomidine (control group). Registration and data management were conducted using an electronic data capturing system. Randomization was conducted by permuted block randomization stratified by study center, presence of emergency surgery, chronic obstructive pulmonary disease, and soft tissue infection. The block size was 4 but physicians and investigators were not notified of this during the study. Patients in the dexmedetomidine group received dexmedetomidine and analgesia continuously, and other sedatives were added as needed. Patients in the control group received sedative drugs such as propofol, midazolam, and analgesia without dexmedetomidine. The targets of sedation depth were a Richmond Agitation-Sedation Scale (RASS) score of 0 (calm) during the day and a RASS score of −2 (lightly sedated) during the night in both groups. 10 Sedation was maintained throughout the duration of mechanical ventilation or as needed. The sedation protocols were also in compliance with the Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult. 11 The detailed sedation protocol is available in eFigure 1 in Supplement 2. The treatment protocol for sepsis was based on the Guidelines for the Management of Sepsis by the Japanese Society of
Primary and Secondary Outcomes
The co-primary outcomes were 28-day mortality and ventilator-free days. In the original protocol, we planned to assess the duration of ventilation as a co-primary outcome. Because duration of mechanical ventilation was highly influenced by mortality, the number of 28-day ventilator-free days was set as the co-primary end point instead on May 2, 2015, before obtaining outcome data. Ventilator-free days were calculated in the first 28 days or the days alive minus days under mechanical ventilation after randomization. Patients were weaned from mechanical ventilation with a spontaneous breathing trial procedure if they met the predefined criteria, including improvement of the underlying illness, a partial pressure of arterial oxygen of more than 60 mm Hg with a fraction of inspired oxygen of less than 0.5 and a positive end-expiratory pressure of less than 8 cm H 2 O, a normal partial pressure of carbon dioxide, and sufficient spontaneous inspiration. The full ventilator-weaning criteria are described in the trial protocol (Supplement 1). Secondary outcomes included length of ICU stay and length of hospital stay (days); RASS score; Confusion Assessment Method for ICU Patients (CAM-ICU) score; Sequential Organ Failure Assessment (SOFA) score 13 ; disseminated intravascular coagulation score (as defined by the Japanese Association for Acute Medicine 14 ); a score comprising Mini-Mental State Examination (MMSE) score at hospital discharge, serum urea nitrogen and creatinine levels, estimated glomerular filtration rate, daily urinary output, requirement for renal replacement therapy, C-reactive protein and procalcitonin levels, daily energy intake by enteral nutrition, and prealbumin level. The RASS is a distinctive scale for the degree of sedation or agitation; thus, it cannot be evaluated with means or medians. Wellcontrolled sedation was defined as an RASS score between −3 and +1 throughout 1 day spent in the ICU and was defined as (rate of controlled sedation) = (patient's number of days with well-controlled sedation)/(total number of patients in the ICU), calculated for each day. Coma was defined as an RASS score between −4 and −5 throughout 1 day in the ICU. The rate of days with well-controlled sedation and days free from delirium or coma were set as post hoc analyses. Predefined adverse events included any arrhythmias and myocardial ischemia such as acute coronary syndrome during sedation.
Statistical Analyses
To estimate the sample size, we assumed the 28-day survival to be 80% in the dexmedetomidine group and 60% in the control group based on the results of the MENDS randomized controlled trial, which showed that the 28-day survival was 84% among the group receiving dexmedetomidine and 59% among the control group. 8 The study needed 172 patients to achieve 80% power with a 2-sided α level of .05. A 15% dropout or withdrawal rate was estimated and 200 patients were planned for enrollment. Clinical outcomes were analyzed according to the intention-to-treat principle. All time-to-event data were censored at 28 days. Missing data were analyzed without imputation, but there were no missing data of observations during the ICU stay. Continuous variables were presented as means with standard deviations or medians with interquartile ranges (IQRs), and categorical variables were shown as numbers and percentages.
Because there were 2 co-primary end points, both comparisons had to meet significance to determine the efficacy of treatment. The cumulative incidence was estimated by the Kaplan-Meier method, and differences between the groups were assessed by the log-rank test. We used the Cox proportional hazards model to estimate the hazard ratio (HR) and 95% confidence interval of the dexmedetomidine group compared with the control group. Proportional hazard assumptions for the variables were assessed on the plots of log(time) vs log(−log [survival]) stratified by the variables, and the assumptions were verified to be acceptable. To compare other clinical outcomes between the dexmedetomidine group and the control group, χ 2 tests or Fisher exact tests were used for categorical variables and t tests or Wilcoxon rank sum tests for continuous variables based on the distribution.
To examine the effect of dexmedetomidine on sedation control and the occurrence of delirium and coma, a generalized linear model (GENMOD procedure with logit function) was used to account for repeated measurements in the same patient. We included the status of patients in the dependent variable and treatment allocation in the independent variable with a repeated variable of patient.
The Cox proportional hazard models were constructed in prespecified subgroups: age (≥65 vs <65 years old), Acute Physiology and Chronic Health Evaluation II (APACHE II) scores (≥23 vs <23), 15 shock on admission (presence vs absence), and site of infection (thorax, abdomen, etc) . Shock was defined as a circulatory SOFA score of 3 or higher. The threshold of APACHE II score was determined by the median value. To estimate P values for interaction, Cox proportional hazards models with variables of outcomes, subgroup factor, and the interaction variables in addition to allocation factors were constructed. We also constructed the same analyses including study center as a stratification variable because management of sepsis might be different between centers. Because this stratification variable was not predetermined, the analyses adjusted for study center were considered post hoc sensitivity analyses. All statistical analyses were conducted by an independent statistician who was masked to treatment group allocation. All statistical analyses were performed using JMP, version 11.2.0 (SAS Institute Inc), and SAS, version 9.4 (SAS Institute Inc). A 2-sided P<.05 was considered statistically significant. The statistical analysis plan for the study is available in Supplement 3.
Results
A total of 203 ventilated patients with sepsis were initially enrolled and 2 patients were excluded (1 declined to participate and 1 had liver cirrhosis). Two hundred one patients were randomized either into the dexmedetomidine group (n = 100)
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or the control group (n = 101) ( Figure 1 ). The patients' backgrounds, severity of illness, comorbidities, and site of infection were similar between groups ( Table 1) .
The cumulative incidence of death at 28 days was 22.8% (n=19) in the dexmedetomidine group and 30.8% (n=28) in the control group (P =.20) (Figure 2 ). The HR of the dexmedetomidine group was 0.69 (95% CI, 0.38-1.22; P = .20). The result of sensitivity analysis adjusting the center was similar (HR, 0.65; 95% CI, 0.36-1.16; P = .15). The median number of 28-day ventilator-free days in the dexmedetomidine group was 20 (IQR, 5-24) compared with 18 (IQR, 0.5-23) in the control group (P = .20). The number of ventilator days was 6 (IQR, 3-11) in the dexmedetomidine group and 6 (IQR, 3-11] in the control group (P = .64). Median length of ICU stay was 7 (IQR, 4-12) days in the dexmedetomidine group and 8 (IQR, (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) days in the control group (P = .43).
There were no significant differences in the daily total SOFA score between groups ( Table 2 ). The rate of well-controlled sedation during ICU stay was significantly higher in the dexmedetomidine group than in the control group (range, 17%-58% vs 20%-39%; P = .01), while the rate of delirium-and comafree days was not significantly different between groups (P =.17) (Figure 3) . The frequency and dose of propofol and midazolam were lower in the dexmedetomidine group than in the control group, but the frequency and dose of fentanyl were not significantly different (eTable 1 in Supplement 2).
The subgroup analyses did not show any heterogeneity in the effect of dexmedetomidine on mortality in terms of age older than 65 years, presence of shock on admission, or site of infection (eFigure 2 in Supplement 2). In the subgroup with APACHE II scores of 23 or higher, the dexmedetomidine group was associated with lower hospital mortality (HR, 0.39; 95% CI, 0.16-0.91; P = .03).
Secondary outcomes included C-reactive protein, procalcitonin, and prealbumin levels and disseminated intravascular coagulation score. There was a significant difference only in C-reactive protein between the groups (eTable 2inSupplement 2). The time taken to achieve a satisfactory MMSE score (or proportion of time spent with a satisfactory MMSE score) could not be reported because of insufficient data obtained.
The observed adverse events included bradycardia in 7 patients (7%) in the dexmedetomidine group and in 2 patients (2%) in the control group. Acute coronary syndrome was noted Overall score 8 (6-11) 9 (5-11)
Respiratory score 2 (1-3) 2 (1-3)
Circulatory score 3 (2-4) 3 (1.5-4)
Renal score 1 (0-2) 1 (0-3) 
Discussion
In this randomized clinical trial to evaluate the effect of dexmedetomidine on clinical outcomes in patients with sepsis under ventilation and to attempt to verify the results of subgroup analysis in the MENDS trial, 8 administration of dexmedetomidine in patients with sepsis did not improve mortality or ventilator-free days but did achieve better control of light sedation. The difference in results between this trial and the MENDS study may be attributable to a number of factors. First, the previous study was a subgroup analysis of patients with sepsis in the MENDS trial in which ventilated ICU patients were randomized to receive dexmedetomidine or lorazepam; second, this trial was a randomized clinical trial of patients with sepsis undergoing ventilation and receiving vs not receiving dexmedetomidine; third, the administered dexmedetomidine dosage in the trial was less than the usual dosage in other countries because of the lower dosage limit covered by Japanese medical insurance; and fourth, the participants in this study were older (mean age of 68.8 vs 59.0 years) and their APACHE II scores were lower (mean of 23.0 vs 29.5) than in the MENDS subgroup analysis.
The study may have identified a clinically important benefit of dexmedetomidine-an 8% reduction in 28-day mortality-that did not demonstrate statistical significance. The trial was prospectively powered to detect a 20% difference in 28-day survival based on the results of the MENDs subgroup analysis. Physicians may consider an 8% difference in 28-day mortality to be clinically significant but this study was underpowered to detect this difference.
Dexmedetomidine reduces prevalence of delirium in those with prolonged ICU sedation compared with midazolam, 16 and delirium is an independent predictor of mortality in patients undergoing mechanical ventilation. 17 Dexmedetomidine has been associated with improved patient communication with Day 2 9 (7-11) 9 (6-13) .51
Day 4 8 (5-11) 8 (4.5-11.5) .67
Day 6 8 (5-10) 7 (4-10) .68
Day 8 7 (5-9) 5 (3-11) .31
Intensive care unit length of stay, median (IQR), d 7 (4-12) 8 (4-14)
.43
Adverse events, No. (%) Bradycardia 7 (7) 2 (2) .10
Acute coronary syndrome 1 (1) 1 (1) nursing staff and a reduction in delirium compared with a γ-aminobutyric acid agonist. 1 The establishment of a systemic sedation protocol and early physical therapy including a ventilator-weaning protocol in the ICU can improve delirium and prognosis. [18] [19] [20] [21] [22] In the current study, with systematic protocolized light sedation, dexmedetomidine treatment was associated with better sedation but not with delirium reduction in patients with sepsis. The systematic sedation protocol might have been more effective than drug choice for reducing delirium. Moreover, it was hypothesized that dexmedetomidine can improve prognosis by suppressing the hypersympathetic condition in sepsis. High plasma catecholamine levels seem to be harmful to the human body in critically ill patients. [23] [24] [25] [26] Consequently, a β 1 -adrenoceptor blockade reduces mortality in patients with sepsis. 27 In another study, heart rate control with esmolol, a typical β 1 -adrenoceptor blockade, was shown to reduce norepinephrine requirements, resulting in an improvement in 28-day survival. 28 Moreover, even the smallest dose of dexmedetomidine suppresses both endogenous norepinephrine and epinephrine in a healthy human body.
29
From these reports, it was considered that dexmedetomidine and β 1 -adrenoceptor blockade could have a similar effect on improving mortality in patients with sepsis.
A new definition of sepsis was announced in February 2016. 30 Owing to the inclusion criteria used in this study, the study enrolled patients with more severe sepsis than specified in the new definition because patients with sepsis who needed mechanical ventilation were included. Therefore, the findings should be applicable to patients with sepsis as defined by the new definition. There are several limitations in this study. First, this was an open-label study and the end points were assessed by physicians at discharge. However, mortality was less likely influenced by physicians' judgment, and the criteria for weaning from mechanical ventilation were set prior to the study. The event adjudication committee also verified assessment and the use of sedative drugs or other interventions for sepsis. The RASS and CAM-ICU were assessed by nurses who were not blinded to the allocation, but they assessed patients based on a manual irrespective of the study. Therefore, the influence of unblinding should be small. Second, the sample size was not large enough to detect the 8% difference in 28-day mortality as a result. We estimated the sample size based on the MENDS subgroup trial, which showed 16% and 41% mortality (a 25% difference). Third, although long-term outcomes are important in this area of research, only short-term outcomes were analyzed in this study. Further studies with long observation periods are warranted.
In this study, only 203 patients were screened and 201 enrolled. The number of patients screened but not enrolled was small for a general clinical trial. In Japan, clinicians ascertain the inclusion and exclusion criteria and decide to offer enrollment. Therefore, patients were screened and enrolled at the same time; there was 1 case excluded for liver cirrhosis before allocation.
Conclusions
Among patients requiring mechanical ventilation, the use of dexmedetomidine compared with no dexmedetomidine did not result in statistically significant improvement in mortality or ventilator-free days. However, the study may have been underpowered for mortality, and additional research may be needed to evaluate this further. To examine the effect of dexmedetomidine on sedation control and the occurrence of delirium and coma, a generalized linear model was used accounting for repeated measurements in the same patient. Well-controlled sedation was defined as a Richmond Agitation-Sedation Scale (RASS) score between −3 and +1 throughout 1 day spent in the intensive care unit (ICU) and was defined as (rate of controlled sedation) = (patient's number of days with well-controlled sedation)/(total number of patients in the ICU), calculated for each day. Coma was defined as an RASS score between −4 and −5 throughout 1 day in the ICU. Day 1 is defined as the first day of randomization into the trial.
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Exclusion criteria 72
Patients will be excluded if they meet any of the following criteria: 1) 73
Severe chronic liver disease (Child B or C); 2) acute myocardial infarction 74 or heart failure (New York Heart Association 4); 3) drug dependence or 75 alcoholism; 4) psychological illness or severe cognitive dysfunction; 5) 76 pregnant or lactating women; 6) patients who are allergic to 77 dexmedetomidine; and 7) attending physician's decision 78 79 80
Study design 81
We will perform an open-label, multicenter, randomized controlled trial 82 with blinded-endpoint assessment. 83 84
Randomization 85
When an attending physician judges that a patient is eligible, they will 86 obtain informed consent from the patient or the patient's family. Then they 87 will register and randomize the patient online by accessing the Internet Duration of sedation will be more than 24 hours. 100
As a general rule, we will not deviate the timing, dose and duration of 101 the study drug from the protocol. 102 103
Outcome measures 104
Co-pPrimary outcome measures: 105 a) 28-day mortality rate 106
The mortality rate of patients after 28 days. 107
b) Duration of mechanical ventilation28-day ventilator free days 108
Originally, the duration of mechanical ventilation in the ICU, including 109 non-invasive ventilation was defined as primary outcome. However, duration 110 of mechanical ventilation was highly influenced by mortality. Therefore, 111
we set 28-days ventilator free days as primary endpoint.
112
The If an unpredictable or a serious adverse event occurs, the attending 229 physician will report the case to the DSMB. The attending physician will 230 cease administration of dexmedetomidine if they consider dexmedetomidine 231 to be harmful to the patient. 232 233
Case registration and data collection 234
We will perform case registration, randomization and data collection 235 online by accessing the INDICE. All researchers will require an ID and a 236 password when they input the data. For randomization, they will need to 237 input the sex, age, emergent surgery and center of the patients.
238
A chief researcher of each center will store the list of randomization 239 numbers and patient IDs securely (e.g. in the security box).
240
We will delete the collected data five years after reporting and 241 publication of the results. 242 243
Planned study duration 244
The planned study duration will be five years after approval has been 245 obtained from the Institutional Review Board of each hospital (three years 246 for patient recruitment). 247 248
Statistical analysis 249
The DESIRE trial has been designed to compare the dexmedetomidine group 250 with the control group. A two-sided P value of less than 0.05 will be 251 considered to indicate a statistical significance.
252
The secondary outcomes of agitation, delirium, arrhythmia, cardiac 253 ischemia, hospital acquired infection and renal replacement therapy will 254 be compared between the two groups using the chi-square test.
255
The 28-day mortality rate, duration of mechanical ventilation, length of 256 ICU stay and duration of hospital stay will be compared between the two 257 groups using the log-rank test. Kaplan-Meier survival curves will be used 258 for graphical presentation.
259
The Wilcoxon signed-rank test will be used to compare the outcomes of renal 260 function, daily urinary output, duration of antimicrobial therapy, 261 inflammatory markers (CRP and PCT), severity score (SOFA score and DIC 262 score), duration of enteral nutrition, doses of other drugs, including 263 sedatives, analgesics and psychoactive drugs, and cognitive function 264 between two groups. 265
We will conduct the subgroup analysis for age (>or = 65 year-old, or< 65 266 year-old), severity score (APACHE II > or = median, or < median), site of 267 infection (abdomen, thorax or others) and shock (cardiovascular SOFA 268 subscore > or = 3, or < 3). 269 270
Sample size determination 271
Planned sample size: 200 cases 272
In the subgroup analysis of sepsis patients in the MENDS trial by 273
Pandharipande PP et al., dexmedetomidine resulted in an increased 28-day 274 survival rate (84% in the dexmedetomidine group versus 59% in the control 275 group). From this, we have estimated that the 28-day survival rate will 276 be 80% in the dexmedetomidine group and 60% in the control group. We have 277 estimated that, with a sample size of 172 patients, the study will have 278 80% power to detect a significant difference using the log-rank test. In the DEX group, we have to continue dexmedetomidine during the mechanical ventilation, but we can stop dexmedetomidine temporally because of the severe circulatory failure.
The definition of weaning from mechanical ventilation was to be free from mechanical ventilation more than 24 hours.
The time of decision to be withdrawing from any treatment was regarded to termination of this study.
22 Oct 2013 We will conduct the subgroup analysis for age (less than 65 years-old or not), severity score (lower than the mean of APACHE II or not), site of infection (abdomen, thorax or not) and with or without circulatory failure (less than 3 point of cardiovascular SOFA subscore or not).We will conduct the subgroup analysis for age, sex, the higher or lower severity score, site of infection, with or without organ failure.
April 2014
We added Kyohei Miyamoto (Wakayama Medical University) to Chief investigator.
We changed affiliation of Takeshi Morimoto, from Kinki University Faculty of Medicine to Hyogo College of Medicine.
Apr 2015
We changed affiliation of Hitoshi Yamamura, from Osaka City University Hospital to Hirosaki University Graduate School of Medicine.
May 2015
We set 28-days ventilator free days as primary outcome instead of the duration of mechanical ventilation in the ICU, because duration of mechanical ventilation was highly influenced by mortality. In the DEX group, we have to continue dexmedetomidine during the 342 mechanical ventilation, but we can stop dexmedetomidine temporally because 343 of the severe circulatory failure. 344
The definition of wean from mechanical ventilation was to be free from 345 mechanical ventilation more than 24 hours. 346
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